

July 14, 2023

NOTICE

The Board of Directors of the Kaweah Delta Health Care District will meet in a Quality Council Committee meeting at 7:30AM on Thursday, July 20, 2023, in the Kaweah Health Lifestyle Fitness Center Conference Room, 5105 W. Cypress Avenue, Visalia, CA 93277.

The Board of Directors of the Kaweah Delta Health Care District will meet in a Closed Quality Council Committee at 7:31AM on Thursday, July 20, 2023, in the Kaweah Health Lifestyle Fitness Center Conference Room, 5105 W. Cypress Avenue, Visalia, CA 93277, pursuant to Health and Safety Code 32155 & 1461.

The Board of Directors of the Kaweah Delta Health Care District will meet in an open Quality Council Committee meeting at 8:00AM on Thursday, July 20, 2023, in the Kaweah Health Lifestyle Fitness center Conference Room, 5105 W. Cypress Avenue, Visalia, CA 93277.

All Kaweah Delta Health Care District regular board meeting and committee meeting notices and agendas are posted 72 hours prior to meetings in the Kaweah Health Medical Center, Mineral King Wing entry corridor between the Mineral King lobby and the Emergency Department waiting room.

The disclosable public records related to agendas are available for public inspection at Kaweah Health Medical Center – Acequia Wing, Executive Offices (Administration Department) {1st floor}, 400 West Mineral King Avenue, Visalia, CA and on the Kaweah Delta Health Care District web page https://www.kaweahhealth.org.

KAWEAH DELTA HEALTH CARE DISTRICT Michael Olmos, Secretary/Treasurer

Cindy Moccio

Board Clerk, Executive Assistant to CEO

Cindy mocció

DISTRIBUTION:

Governing Board, Legal Counsel, Executive Team, Chief of Staff http://www.kaweahhealth.org



KAWEAH DELTA HEALTH CARE DISTRICT BOARD OF DIRECTORS QUALITY COUNCIL

Thursday, July 20, 2023 5105 W. Cypress Avenue Kaweah Health Lifestyle Fitness Center Conference Room

ATTENDING:

Board Members; David Francis – Committee Chair, Michael Olmos; Gary Herbst, CEO; Keri Noeske, RN, BSW, DNP, Chief Nursing Officer; William Brien, MD, CMO/CQO, Daniel Hightower, MD, Chief of Staff and Professional Staff Quality Committee Chair; Lamar Mack, MD, Quality and Patient Safety Medical Director; Sandy Volchko DNP, RN CLSSBB, Director of Quality and Patient Safety; Ben Cripps, Chief Compliance and Risk Management Officer; Evelyn McEntire, Director of Risk Management; and Sylvia Salinas, Recording.

OPEN MEETING – 7:30AM

- **1.** Call to order David Francis, Committee Chair
- 2. Public / Medical Staff participation Members of the public may comment on agenda items before action is taken and after it is discussed by the Board. Each speaker will be allowed five minutes. Members of the public wishing to address the Board concerning items not on the agenda and within the jurisdiction of the Board are requested to identify themselves at this time. For those who are unable to attend the beginning of the Board meeting during the public participation segment but would like to address the Board, please contact the Board Clerk (Cindy Moccio 559-624-2330) or cmoccio@kaweahhealth.org to make arrangements to address the Board.
- 3. Approval of Quality Council Closed Meeting Agenda 7:31AM
 - Quality Assurance pursuant to Health and Safety Code 32155 and 1461 Daniel Hightower,
 MD, Chief of Staff and Professional Staff Quality Committee Chair
 - Quality Assurance pursuant to Health and Safety Code 32155 and 1461 Evelyn McEntire, RN, BSN, Director of Risk Management and Ben Cripps, Chief of Compliance and Risk Officer.
- 4. Adjourn Open Meeting David Francis, Committee Chair

CLOSED MEETING - 7:31AM

- 1. Call to order David Francis, Committee Chair & Board Member
- Quality Assurance pursuant to Health and Safety Code 32155 and 1461 Daniel Hightower, MD, Chief of Staff and Professional Staff Quality Committee Chair

Thursday, July 20, 2023 - Quality Council

- **3.** Quality Assurance pursuant to Health and Safety Code 32155 and 1461 Evelyn McEntire, RN, BSN, Director of Risk Management, and Ben Cripps, Chief Compliance and Risk Officer.
- **4.** Adjourn Closed Meeting David Francis, Committee Chair

OPEN MEETING – 8:00AM

- **1.** Call to order David Francis, Committee Chair
- 2. Public / Medical Staff participation Members of the public wishing to address the Committee concerning items not on the agenda and within the subject matter jurisdiction of the Committee may step forward and are requested to identify themselves at this time. Members of the public or the medical staff may comment on agenda items after the item has been discussed by the Committee but before a Committee recommendation is decided. In either case, each speaker will be allowed five minutes.
- **3. Written Quality Reports** A review of key quality metrics and actions associated with the following improvement initiatives:
 - 3.1. <u>Best Practice</u> Team Update (deferred from June)
 - 3.2. Rural Health Clinics Quality Improvement Program (QIP)
 - 3.3. Stroke
 - 3.4. Sepsis Quality Focus Team
- 4. Environmental Services Adenosine Triphosphate (ATP) Testing and Methicillin-Resistant Staphylococcus Aureus (MRSA) Quality Focus Team Report Action plan related to improve our performance and what we can expect to see in the coming quarters on the disinfection rates we are experiencing in the terminal cleaning of our patient rooms. Tendai R. Zinyemba, MBA, MSMIS, CHESP, Director Environmental Services, Laundry, & Patient Transport
- **5.** Clinical Quality Goals Update- A review of current performance and actions focused on the clinical quality goals for Sepsis, and Healthcare Acquired Infections. Sandy Volchko, RN, DNP, Director of Quality and Patient Safety.
- **6. Adjourn Open Meeting** *David Francis, Committee Chair*

In compliance with the Americans with Disabilities Act, if you need special assistance to participate at this meeting, please contact the Board Clerk (559) 624-2330. Notification 48 hours prior to the meeting will enable the District to make reasonable arrangements to ensure accessibility to the Kaweah Delta Health Care District Board of Directors committee meeting.

Best Practice Team Update

Michael Tedaldi, MD - Kaweah Health Medical Director of Best Practice Teams Sandy Volchko, Director of Quality & Patient Safety Wendy Jones, Director of Respiratory Services Molly Niederreiter, Director of Rehabilitation Services **Emma Mozier, Director of Medical-Surgical** Christine Aleman, Director of Cardiovascular Operations

July 2023















Kaweah Health Best Practice Teams



- ACE Angiotensin Converting Enzyme inhibitors (medication to treat heart failure)
- ARBs Angiotensin-Receptor Blocker (medication to treat heart failure)
- ARNI Angiotensin Receptor-Neprilysin Inhibitor (medication to treat heart failure)
- AMI-NSTEMI Acute Myocardial Infarction Non-ST Elevated Myocardial Infarction
- BB Beta Blocker (heart medication)
- CAP Community Acquired Pneumonia
- CHFrEF ("reduced EF" or "systolic HF")
- CKD Chronic Kidney Disease

Acronyms

- CMS Centers for Medicare & Medicaid Services
- COPD Chronic Obstructive Pulmonary Disease
- CPG Clinical Practice Guideline
- CPW Care Pathway

- D denominator
- ED Emergency Department
- EF Ejection Fraction
- EKG electrocardiogram
- FYTD Fiscal Year to Date
- GFR glomerular filtration rate
- GOLD Standards Global Initiative for Chronic Obstructive Lung Disease
- HF Heart Failure
- KPI Key Performance Indicator
- LOS Length of stay
- N Numerator
- O/E Observed divided by Expected
- PN Pneumonia
- QI Quality Improvement
- SARA Selective Aldosterone Receptor Antagonist





Kaweah Health Best Practice Teams

Goal: Improve patient outcomes by standardizing care on 4 key patient populations (AMI- NSTEMI, COPD, HF & PN)

- Standardized care based on Clinical Practice Guideline (CPGs) and operationalize the standardized care through provider power plans
- 4 "Core Teams" established for each population, includes Medical Director, Quality Facilitator, Operational Director & Advanced Nurse Practitioner (APN), and Clinical Educator
- Outcomes include: Mortality, Readmission and Length of Stay







Best Practice Teams



AMI (non-STEMI), COPD, Heart Failure & Pneumonia

Initiation



Phase I



Phase II

- Prioritized & staggered
- Team
 identification:
 Q&P/S
 Facilitator, MD
 Champion, RN
 Director, process
 stakeholders
- Best Practice Guideline selection

Goal: Identify clinical processes that will yield optimal patient outcomes

- Clinical KPIs Selection
- Measures defined
- Dashboard developed
- Initial QI work (ie. power plan optimization/ work flow) to achieve targets


Goal: Identify KPIs that will reduce mortality o/e & complications (2° LOS & Readmission)

- Clinical Practice
 Guidelines
 integrated into
 Cerner power
 plans &
 workflow
- QI Measures added to dashboard
- QI work to achieve targets

Goal: Improve efficiency and further reductions in LOS, mortality o/e & readmission



Kaweah Health Best Practice Teams 2021-24 Gantt Chart



WEEKS STARTING OCT 2021 THROUGH JULY 2022

Duration of Task by Week

Dark = Complete, Light = Incomplete



Outcome Data



Kaweah Health Best Practice Teams Outcome Dashboard FY 2022-23

| | Population | Baseline (FY 2019) | FY22 July 21-June 22* | FY2023 Goals | 3Q 2022 | 4Q2022 | 1Q2023 | Apr-23 | May-23 | FYTD 2023 |
|--------------------------------------|--------------------|-----------------------|--------------------------|-----------------|---------------|---------------|---------------|---------------|--------------|-----------------|
| Readmission Medicare Population | AMI (non-STEMI) | 12.34% | 7.35% (5/68) | 7.16% | 3.84% (1/26) | 15.39% (2/13) | 15.00% (2/20) | 20.00% (1/5) | 9.10% (1/11) | 10.67% (8/75) |
| missic | COPD | 16.09% | 23.53% (8/34) | 12.87% | 8.3% (1/12) | 12.50% (2/16) | 12.50% (1/8) | 0.0% (0/2) | 33.33% (1/3) | 12.20% (5/41) |
| eadr | HF | 18.22% | 13.02% (25/192) | 11.72% | 20.69% (6/29) | 4.88% (2/41) | 18.18% (8/44) | 31.25% (5/16) | 0.0% (0/14) | 14.58% (21/144) |
| Medi: | PN Viral/Bacterial | 14.13% | 16.67% (27/162) | 11.30% | 2.70% (1/37) | 6.25% (3/48) | 9.52% (4/42) | 0.0% (0/12) | 9.09% (2/22) | 6.21% (10/161) |
| ioi | AMI (non-STEMI) | 0.75 | 0.99 (n=49) | 0.71 | 0.0 (n=14) | 0.0 (n=6) | 0.0 (n=17) | 0.0 (n=3) | 0.95 (n=6) | 1.09 (n=46) |
| tality pulat | COPD | 2.4 | 1.41 (n=40) | 0.93 | 0.0 (n=10) | 0.0 (n=16) | 0.0 (n=8) | 0.0 (n=2) | 0.0 (n=3) | 0.0 (n=39) |
| O/E Mortality Medicare Population | HF | 1.78 | 0.52 (223) | 0.52 | 1.79 (n=44) | 1.41 (n=53) | 0.68 (n=53) | 1.47 (N=22) | 0.0 (n=19) | 1.10 (n=191) |
| O/F | PN Bacterial | 1.85 | 0.53 (n=43) | 0.53 | 0 (n=7) | 0 (n=6) | 0 (n=10) | 1.73 (N=4) | 1.22 (n=8) | 0.91 (n=35) |
| Σ | PN Viral | 1.34 | 1.09 (n=109) | 0.81 | 0 (n=18) | 0.40 (n=37) | 0.84 (n=34) | 0 (n=11) | 2.56 (n=13) | 0.68 (n=113) |

^{*}FY24 Midas updated version 5 will be used for all outcome data





COPD Best Practice Team

Key performance indicators of focus:

- Pulmonary Function Tests (PFT) performed, 10% of patients have PFTs performed, goal is to increase the volume to 30% in 6 months
- Pneumococcal vaccine rates, 8% of patients accept and receive the vaccine prior to discharge, goal is to increase the rate of pneumococcal vaccines to 50% in 6 months
- Patient acceptance of smoking cessation education, 32% of eligible patients accept smoking cessation education, goal is to increase acceptance to 50% in 6 months

Current QI actions:

- Dr. Tedaldi attends monthly Hospitalist/Critical Care meeting to encourage utilization of the COPD Admission powerplan and provide education on when and what type of PFT to order.
- Respiratory Therapists assess patients' readiness for bedside PFTs and communicate this to the bedside nurses and/or providers





COPD Best Practice Team

Current QI actions continued:

- Propose changes to nursing discharge summary form in EMR, which includes patient specific details about eligibility for the pneumonia vaccine
- Propose changes to nursing discharge summary form in EMR, which includes details about patient's smoking status

Barriers:

• PFT results do not automatically flow into EMR. Results are scanned into the EMR, requiring extra steps for providers to locate and access PFT results.





Heart Failure Best Practice Team

Key performance indicators of focus:

- Increase usage of CARD HF Admission Power plan for HF inpatients, overall 47% of power plan usage is observed, goal is to improve rate to 75% by 12/31/23
- Increase use of Entresto for systolic heart failure patients during hospital stay & at discharge, 18% of patient received Entresto during hospital stay & 9% are Rx Enteresto at discharge, goal is to improve rate to 50% for patients that have selected insurance (payers that cover Entresto) by 12/31/23
- Increase use of Beta Blocker for systolic heart failure patients at hospital discharge, 39% of patients are Rx BB at discharge, goal is to improve rate to 75% by 12/31/23

Current QI actions:

- Dr. Michael Tedaldi spearheading Physician outreach: educating in monthly dept. meetings, educating residents regarding order sets, partnering with ISS to assist providers to update HF power plan to their favorites
- Drill down to provider specific fall outs





Heart Failure Best Practice Team

Current QI actions Cont.:

- Review data & identify if ACE/ARB available & check if pt candidate to switch to Entresto
- Split Entresto KPI: Inpatient vs. Rx at discharge to identify opportunities (COMPLETED)
- Explore feasibility of Nurse Practitioner consult: Chart biopsy & Re-start core measure checks
- HF BPT to utilize Heart Failure Medication Checklist & eventually to be used by providers on discharge

Barriers:

- Unable to retrieve Ejection Fraction numerical value directly into EMR, Syngo analytics is not sync to Cerner
- Limited amount of insurance companies covering Entresto
- Difficulty in evaluating contraindications to using full GDMT (Guideline Directed Medical Therapy)





Pneumonia Best Practice Team

Key performance indicators of focus:

- Antibiotics administered within 3 hours, internal data shows 1.4% of patients receive antibiotics within 3 hours, goal is to increase volume of antibiotics administered within 3 hours to 50% in 6 months
- Transition of IV to oral antibiotics within 48 hours, 1.6% of patients transition from IV to oral within 48 hours, goal is to increase rate of transition to oral antibiotics within 48 hours to 50% in 6 months
- Utilization of Pneumonia admission powerplan, powerplan is ordered on 21% of admissions, goal is to increase rate of ordering powerplan to 50% in 6 months

Current QI actions:

- Data analysis to evaluate root causes for untimely antibiotic administration
- Collaborate with Antimicrobial Stewardship Team and Pharmacy





Pneumonia Best Practice Team

Current QI actions continued:

- Encourage providers to save most current Pneumonia Admission powerplan to favorites
- Data analysis on non Pneumonia Admission powerplan utilization
- Dr. Tedaldi attends monthly Hospitalist/Critical Care meeting to encourage utilization of the powerplan

Barriers:

- Variability in process of ordering antibiotics presents challenges on how to best capture data
- Utilization of powerplans is recommended not required





AMI NSTEMI Best Practice Team

Current actions:

- Cardiovascular staff are currently abstracting data for the KPI's that were identified by the AMI NSTEMI Best Practice Team.
- Once data is abstracted the team will identify which Key Performance Indicator(s) require their focus.

Barriers:

• Data abstraction and the population of the AMI NSTEMI dashboard with that data is a manual process



Team Charter

Pneumonia (PN)

Key Initiatives August 2023

- Dashboard complete
- Promote utilization of Pneumonia Admission powerplan to operationalize best practices for antibiotic type and transition of IV to oral antibiotics at Hospitalist/Critical Care meetings
- Data analysis/current state review

| DIRECTOR: Molly Niederreiter PROBLEM STATEMENT: Mortality, readmission and LOS data indicates opportunity in standardizing care and reducing variation through clinical practice guideline and care pathway implementation. SCOPE: (WHAT DOES THIS INCLUDE AND NOT INCLUDE?) Includes CAP patients in Emergency Department and admitted into the Medical Center FINANCIAL IMPLICATIONS: Penalties associated with the CMS Value-Based Purchasing Program (mortality), penalties associated with CMS Readmission Reduction Program & reputational costs with CMS star ratings. APN: Katelyn Williams SHORT TERM PROJECT GOALS: LONG TERM PROJECT GOALS: 1. Reduce mortality by 20% from 2019 baseline 2. Reduce readmissions by 20% from 2019 baseline 3. Reduce Length of Stay MEASURES: KPIS (in order of priority) 1. Percent of patients who receive first dose of antibiotic administered within 3 hours ion In patients 2. Percent of patients who transition from IV to PO antibiotics within 48 hours of first antibiotic treatment 3. Percent of utilization of Pneumonia Admission powerplan Future KPIS • Rate of documented Pneumonia Severity Index (PSI) | PROJECT NAME: Pneumonia BPT | CHAMPION: Dr. M. Tedaldi | QI Facilitator: Stacey Cajimat |
|---|---|---|---|
| Mortality, readmission and LOS data indicates opportunity in standardizing care and reducing variation through clinical practice guideline and care pathway implementation. SCOPE: (WHAT DOES THIS INCLUDE AND NOT INCLUDE?) Includes CAP patients in Emergency Department and admitted into the Medical Center FINANCIAL IMPLICATIONS: Penalties associated with the CMS Value-Based Purchasing Program (mortality), penalties associated with CMS Readmission Reduction Program & reputational costs with CMS star Nortality, readmission and LOS data indicates (CPGs) COMPLETE 2. Develop Key Performance Indicators (KPIs) COMPLETE 3. Develop dashboards for outcome and KPIs COMPLETE 4. Improve KPI performance IN PROCESS 1. Select clinical practice guidelines (CPGs) COMPLETE 2. Develop Key Performance Indicators (KPIs) COMPLETE 3. Develop Key Performance Indicators (KPIs) Complete Indicators (KPIs) Complete Indicators (KPIs) Complete Indicators (KPIs) Complete Indicators | DIRECTOR: Molly Niederreiter | APN: Katelyn Williams | ET SPONSOR: Dr. W. Brien |
| AND NOT INCLUDE?) Includes CAP patients in Emergency Department and admitted into the Medical Center 1. Percent of patients who receive first dose of antibiotic administered within 3 hours ion In patients Penalties associated with the CMS Value-Based Purchasing Program (mortality), penalties associated with CMS Readmission Reduction Program & reputational costs with CMS star KPIs (in order of priority) 1. Percent of patients who receive first dose of antibiotic administered within 3 hours ion In patients 2. Percent of patients who transition from IV to PO antibiotics within 48 hours of first antibiotic treatment 3. Percent of utilization of Pneumonia Admission powerplan Future KPIS Pate of documented Pneumonia Soverity Index (PSI) | Mortality, readmission and LOS data indicates opportunity in standardizin care and reducing variation through clinical practice guideline and care pathway implementation. | 1. Select clinical practice guidelines (CPGs) COMPLETE 2. Develop Key Performance Indicators (KPIs) COMPLETE 3. Develop dashboards for outcome and KPIs COMPLETE 4. Improve KPI performance IN PROCESS | Reduce mortality by 20% from 2019 baseline Reduce readmissions by 20% from 2019 baseline |
| | AND NOT INCLUDE?) Includes CAP patients in Emergency Department and admitted into the Medical Center FINANCIAL IMPLICATIONS: Penalties associated with the CMS Value-Based Purchasing Program (mortality), penalties associated with CMS Readmission Reduction Prograr & reputational costs with CMS star ratings. | KPIs (in order of priority) Percent of patients who receive first dose of antibio patients Percent of patients who transition from IV to PO an antibiotic treatment Percent of utilization of Pneumonia Admission pow Future KPIS Rate of documented Pneumonia Severity Inde | tibiotics within 48 hours of first verplan |
| Initiation Team identification and guideline selection | Initiation Team identification | tion and guideline selection | |
| Phase I Key Performance Indicator selection, plan and initiate QI activities to achieve KPI goals | Phase I Key Performan | ce Indicator selection, plan and initiate QI activities to achieve KPI | goals |
| Phase II Integration of Clinical Practice Guidelines, measure expansion, dashboard development | Phase II Integration of C | linical Practice Guidelines, measure expansion, dashboard develo | pment |



Team Charter Heart Failure (HF)

Key Initiatives August 2023

- Dashboard Complete
- HF Order set revisions now live operationalize best practices including: addition of medication options with specific evidenced-based parameters (ie. Aldactone, Hydralazine, Entresto
- Ongoing Physician educational outreach
- Identify Physician specific opportunities
- Heart Failure Medication Checklist now live
- Review data & identify if ACE/ARB available & check if pt candidate to switch to Entresto

Next steps:

 Working with Population Health on frequently admitted patients

| PROJECT NAME: | Heart Failure | CHA | AMPION: Dr. M. | QI Facilitator: Erik | ka Pineda |
|---|---|---------------------------|--|------------------------|---|
| | | Ted | laldi | | |
| DIRECTOR: Emm | na Mozier | API | N: Cody Ericson | ET SPONSOR: Wil | liam Brien |
| PROBLEM STATE | EMENT: | PRC | JECT GOAL: | | LONG TERM PROJECT GOALS: |
| Mortality, readmining cares standardizing care variation through guideline and care implementation. | re and reducing oclinical practice re pathway | 2. De COM 3. De COM 4. Im | elect clinical practice guideling MPLETE evelop Key Performance India MPLETE evelop dashboards for outcomprove KPI performance PROCESS | cators (KPIs) | 1. Reduce mortality by 20% from 2019 baseline 2. Reduce readmissions by 20% from 2019 baseline 3. Reduce Length of Stay |
| SCOPE: (WHAT D | OES THIS | ME | ASURES: | | |
| INCLUDE AND N | OT INCLUDE?) | KPI: | s (in order of priority) | | |
| Medical Center pi | rocesses | 1. | What percentage of par | tients with Systolic | Heart Failure (EF <40%) are |
| | | | discharged on correct I | BB, ACE/ARB/ARNI/ | SARA |
| FINANCIAL IMPL | ICATIONS: | | 1b. contraindicati | ons to (goal directe | d) med therapy documented |
| Penalties associa | ted with the CMS | | appropriately? I.E | Bradycardia/ hypo | tension for BB as well as CKD Stage |
| Value-Based Purc | chasing Program | | 3b and greater(GF | R≤30) and or serur | n potassium above 5 meq |
| (mortality), penal | ties associated with | 2. | What percentage of ou | r patients with CHF | rEF ("reduced EF" or "systolic HF") |
| CMS Readmission | n Reduction | | that are eligible have b | een switched over | to Entresto (ARNI) in house? |
| Program & reputa | ational costs with | 3. | Percent of patients who | o started on ACE an | nd d/c'd on an ARNI (Entresto) |
| CMS star ratings. | | | | | |
| TIMELINE & PLAI | N: | | | | |
| Initiation | Team identification | and | guideline selection | | |
| Phase I | Key Performance Inc | dicat | or selection, plan and in | itiate QI activities t | o achieve KPI goals |
| Phase II | Integration of Clinica | | actice Guidelines, measu | ıre expansion, dash | nboard development Kaweah Health . |

Team Charter

Chronic Obstructive Pulmonary Disease (COPD)

Key Initiatives August 2023

- Dashboard complete
- Promote utilization of COPD Admission powerplan to operationalize best practices: Antibiotic options, steroid dosing/frequency, defining medication based on GOLD category, delineating medications for acute and maintenance therapy, PFTs (bedside or outpatient) at Hospitalist/Critical Care meetings

| SCOPE: (WHAT DOES THIS INCLUDE AND NOT INCLUDE?) Inpatient admissions and discharges. FINANCIAL IMPLICATIONS: Penalties associated with the CMS Value-Based Purchasing Program (mortality), penalties associated with CMS Readmission Reduction Program & reputational costs with CMS star ratings. FIMELINE & PLAN: Initiation Team identification Phase I Key Performance | D BPT | CHAMPION: Dr. M. Tedaldi | QI Facilitator: Stacey Cajimat | | | | | | | |
|---|---|---|--|--|--|--|--|--|--|--|
| DIRECTOR: Wendy Jon | ies | APN: Emma Camarena | SPONSOR: Keri Noeske | | | | | | | |
| Mortality, readmission and indicates opportunity in sta and reducing variation thro | LOS data Indardizing care Iugh clinical | LONG TERM GOALS: 1. Select clinical practice guidelines (CPGs) 2. Develop Key Performance Indicators (KPIs) 3. Develop dashboards for outcome and KPIs 4. Improve KPI performance IN PROCESS LONG TERM GOALS: 1. Reduce mortality from 2.40 to 1.92, FY 22 (-20% from 2019 baseline)) 2. Reduce readmissions from 16.09 per 12.87%, by end of FY 22. (-20% from 20 baseline) 3. Reduce Length of Stay | | | | | | | | |
| SCOPE: (WHAT DOES | THIS INCLUDE | MEASURES: | | | | | | | | |
| AND NOT INCLUDE?) In | npatient | KPIs (in order of priority) | | | | | | | | |
| admissions and discharg | es. | Percent of patients with Pulmonary Percent of patients who receive Pnatients | · · · · | | | | | | | |
| associated with the CMS Va Purchasing Program (morta associated with CMS Readn | lue-Based ality), penalties nission | 3. Percent of patients who accept smo | oking cessation information on discharge | | | | | | | |
| TIMELINE & PLAN: | | | | | | | | | | |
| Initiation | | on and guideline selection | | | | | | | | |
| | - | e Indicator selection, plan and initiate | | | | | | | | |
| Phase II | Integration of CI | inical Practice Guidelines, measure e | expansion, dashboard development | | | | | | | |



Team Charter

Acute Myocardial Infarction - Non ST Elevated Myocardial Infarction (AMI - NSTEMI)

Key Initiatives August 2023

- Dashboard under development
- CPGs and order set(s) reviewed for alignment
- Order set revisions completed and approved for 4 different order sets that intersect with care of NSTEMI population
- Operationalizing best practices through order set utilization: adding and revising medication orders and lab test to align with CPGs and pre-checking options
- Data analysis and current state

| PROJECT NAME: AMI Non-STEMI BPT | CHAMPION: Dr. Michael Tedaldi | Quality RN Facilitator: Cindy Vander Schuur |
|--|---|--|
| DIRECTOR: Christine Aleman | APN: Cody Ericson | ET SPONSOR: Keri Noeske |
| PROBLEM STATEMENT: Mortality, readmission, and length of stay (LOS) data indicates opportunity in standardizing care and reducing variation through clinical practice guideline and care pathway implementation. | SHORT TERM PROJECT GOALS: 1. Select clinical practice guidelines (COMPLETE 2. Develop Key Performance Indicato (KPIs) COMPLETE 3. Develop dashboards for outcome at KPIs IN PROGRESS 4. Improve KPI performance NEXT ST | 2. Reduce readmissions by 10% from 2019 rs baseline 3. Reduce length of stay |
| SCOPE: (WHAT DOES THIS INCLUDE AND NOT | MEASURES: KPIs (in order of priority) | |
| *Inpatient Medical Center processes. GUIDELINES: *Denominator: Patients with a diagnosis of NSTEMI who went to the Cath Lab. NSTEMI Definition: 1. Negative EKG (no ST elevation) 2. Positive Troponin resulted ≥ 0.5 *Baseline Data: Monthly starting July 2021 FINANCIAL IMPLICATIONS: Penalties associated with the CMS Value-Based Purchasing Program (mortality), penalties associated with CMS Readmission Reduction Program & reputational costs with CMS star ratings. | Percent of NSTEMI patients admit Troponin. Percent of NSTEMI patients who subcutaneous (SQ) Lovenox (1mg/d). Diagnostic Consideration/Measu done within 4 hours. (for risk strainitial Troponin. Diagnostic Consideration/Measu within 4 hours. (for risk stratificat for NSTEMI patients who undergod DAPT (dual antiplatelet therapy: a contraindication such as aspiring the stratificat for the subcut of the subcut of | have a 12 lead EKG done within 10 minutes of arrival. Inistered oral beta blockers within 24 hours of positive received IV UFH (unfractionated Heparin) or therapeutic g/kg) within one hour of positive Troponin result. re: Percent of NSTEMI patients with a second Troponin tification and early diagnosis) Using resulted time of re: Percent of NSTEMI patients with a second EKG done ion and early diagnosis) co revascularization: Percent of patients discharged on Plavix, Effient, or Brilinta with aspirin) that do not have a sensitivity or history of gastrointestinal bleeding. ACS/NSTEMI Admission order set. |
| TIMELINE & PLAN: | | |
| Initiation Team identification and guideline sele | | (DL |
| | olan and initiate QI activities to achieve h lines, measure expansion, dashboard de | RPI goals evelopment. Address order sets inc. medication orders |





Big Picture Next Steps

- Post medical staff event continue connect with hospitalists to ensure smooth transition to new order sets
- Develop and refine dashboards for each team so improvement is targeted
- Improve Key Performance Indicators through addressing identified root causes



Thank you

Live with passion.

Health is our passion. Excellence is our focus. Compassion is our promise.



Unit/Department Specific Data Collection Summarization

Professional Staff Quality Committee/Quality Improvement Committee

Unit/Department:

ProStaff/QIC Report Date: 5/31/2023

Rural Health Clinics (Exeter/Dinuba/Lindsay/Woodlake/Tulare)

Measure Objectives/Goals:

Behavioral Health PHQ9 Screening TARGET 53% (HRSA 25th percentile) of patients presenting to the rural health clinics will have PHQ9 completed annually.

Controlling High Blood Pressure GOAL 74% (HRSA 90th percentile) of patients presenting to the rural health clinic with diagnosis of hypertension will have blood pressure controlled at 140/90 or less.

| | 2022 | | | | | | | | | | | | | | |
|----------------------------|--------------------|--------|--------|------------------|------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------|
| PHQ-9 DEPRESSION SCREENING | Baseline | Target | Apr-22 | May-22 | Jun-22 | Jul-22 | Aug-22 | Sep-22 | Oct-22 | Nov-22 | Dec-22 | Jan-23 | Feb-23 | Mar-23 | Total |
| DINUBA RHC | 18% | 53% | 24% | 38% | 39% | 43% | 40% | 27% | 18% | 15% | 19% | 21% | 16% | 18% | 26% |
| EXETER RHC | 38% | 53% | 16% | 21% | 26% | 24% | 22% | 21% | 42% | 41% | 40% | 40% | 37% | 38% | 31% |
| LINDSAY RHC | 26% | 53% | 18% | 35% | 35% | 32% | 35% | 28% | 13% | 15% | 30% | 34% | 37% | 26% | 28% |
| TULARE RHC | 31% | 53% | 52% | 50% | 48% | 38% | 18% | 10% | 48% | 51% | 50% | 50% | 34% | 31% | 40% |
| WOODLAKE RHC | 16% | 53% | 11% | 9% | 10% | 15% | 12% | 13% | 15% | 18% | 16% | 14% | 18% | 18% | 14% |
| | 2022 | | | | | | | | | | | | | | |
| HYPERTENSION CONTROLLED | Baseline | Target | Apr-22 | May-22 | Jun-22 | Jul-22 | Aug-22 | Sep-22 | Oct-22 | Nov-22 | Dec-22 | Jan-23 | Feb-23 | Mar-23 | Total |
| DINUBA RHC | 71% | 74% | 77% | 79% | 81% | 79% | 82% | 84% | 82% | 79% | 76% | 77% | 79% | 81% | 80% |
| EXETER RHC | 75% | 74% | 74% | 67% | 71% | 68% | 69% | 78% | 75% | 84% | 72% | 76% | 75% | 85% | 75% |
| LINDSAY RHC | 72% | 74% | 81% | 76% | 76% | 71% | 76% | 71% | 69% | 84% | 83% | 77% | 74% | 74% | 76% |
| TULARE RHC | 74% | 74% | 88% | 80% | 89% | 83% | 92% | 75% | 69% | 67% | 73% | 76% | 67% | 76% | 78% |
| WOODLAKE RHC | 72% | 74% | 69% | 67% | 65% | 64% | 67% | 68% | 76% | 67% | 74% | 74% | 75% | 78% | 70% |
| KEY | Not me goal/ben | | | 10%of nchmark | Meeti Outperf goal/ben | orming | | | | | | | | | |

Denominator = Patients aged 12+ seen at RHCs for outpatient visit during timeframe indicated.

Numerator = Patients from denominator who were screened with the PHQ-9 tool within the 12 months prior to the visit date.

Denominator = Patient aged 18+ with an in-person visit at an RHC location in the timeframe indicated <u>with</u> a prior diagnosis of Hypertension.

Numerator = Patients from the denominator who had documentation of both a Systolic and Diastolic value below the threshold of SBP <140 AND DBP <90

Date range of data evaluated:

12 rolling months (4/1/2022-3/31/2023)

Analysis of all measures/data: (Include key findings, improvements, opportunities)

The <u>Behavioral Health PHQ9 Screening</u> is a measure identified as an area of focus for improvement. Clinical staff are to perform PHQ9 screenings on all patients annually in an effort to capture behavioral health concerns and refer high-risk patients to additional behavioral health services. The data during this reporting period reflected RHC Dinuba-26%, RHC Exeter-31%, RHC Lindsay-28%, RHC Tulare-40%, and RHC Woodlake-14% of rural health clinic patients with an annual PHQ9 screening completed. Our combined goal for the Rural Health Clinics is 53% which represents the 25th percentile. Due to this measure only being performed once a year, it is often missed by clinical staff. Clinical staff fails to review Patient Advisories for health maintenance items needing follow-up.

The <u>Controlling High Blood Pressure</u> is a measure identified as an area of focus for improvement. The goal for this measure is to maintain 74% of hypertensive rural health patients under control which represents the 90th percentile. Efforts towards this measure include ordering free blood pressure cuffs to patients, educating *Please submit your data along with the summary to your PI liaison 2 weeks prior to the scheduled report date.*

Unit/Department Specific Data Collection Summarization

Professional Staff Quality Committee/Quality Improvement Committee

clinical staff on the appropriate workflows regarding repeating blood pressure checks when first BP is high, and referring uncontrolled hypertensive patients to a pharmacist for medication co-management with their primary care provider. The data during this reporting period reflected RHC Dinuba-80%, RHC Exeter-75%, RHC Lindsay-76%, RHC Tulare-78%, and RHC Woodlake-70% of rural health clinic patients that had a diagnosis of hypertension whose blood pressure was controlled at 140/90 or less. The data during this reporting period reflects 4 out of the 5 Rural Health Clinics met or exceeds the performance goal of 74% or 90th percentile.

If improvement opportunities identified, provide action plan and expected resolution date:

<u>Behavioral Health PHQ9 Screening –</u> The performance data will be shared with clinic providers and staff on an ongoing basis during monthly provider meetings and staff meetings. In addition to sharing the data, workflows will be reviewed with clinical staff and training will be provided to those who require it. Reports will be generated on a monthly basis to carefully monitor clinic performance. These reports are granular and generate data down to the employee level identifying who is not completing the required screenings.

<u>Controlling High Blood Pressure –</u> The performance data will be shared with clinic providers and staff on an ongoing basis during monthly provider meetings and staff meetings. In addition to sharing the data, workflows will be reviewed with clinical staff and training will be provided to those who require it. Reports will be generated on a monthly basis to carefully monitor clinic performance. Processes have been hardwired with staff as 4 out of 5 Rural Health Clinics have met or exceeded performance goal.

Monthly Clinical Lead meetings have been established to drive clinical performance in the outpatient clinics. These meetings are led by the RN over Clinical Operations and a Clinical Lead LVN. The attendees are clinical leads representing all clinic locations. During these meetings, the clinical team will review quality data and action plan areas identified needing improvement.

Next Steps/Recommendations/Outcomes:

Monitor data, share with providers and front line staff. Work with ISS to improve data capture capabilities within the EHR. Add complimentary measure data to the next Clinic Prostaff report, which will allow a comprehensive view of screening for clinical depression and follow up throughout the clinic network.

Submitted by Name:

Date Submitted:

Ivan Jara- Director of Outpatient Clinics

5/31/2023


Crystal Clark- Population Health Data Analytics Supervisor

Please submit your data along with the summary to your PI liaison 2 weeks prior to the scheduled report date.


| | Bench- marks | 2021 | Jan'22 | Feb | Mar | Apr | May | June | July | Aug | Sep | Oct | Nov | Dec | Jan'23 | Feb | Mar |
|--|-----------------|------|--------|-------|------|------|------|------|------|------|-------|-------|------|------|--------|------|-------|
| Grouping of Stroke Patients | | | | | | | | | | | | | | | | | |
| Ischemic | | 409 | 36 | 25 | 33 | 43 | 33 | 24 | 23 | 45 | 26 | 29 | 24 | 42 | 33 | 38 | 34 |
| Hemorrhagic | | 93 | 4 | 6 | 7 | 14 | 7 | 10 | 8 | 4 | 11 | 5 | 9 | 6 | 7 | 8 | 10 |
| TIA (in-patient and observation) | | 221 | 13 | 15 | 26 | 20 | 25 | 16 | 12 | 24 | 21 | 7 | 19 | 13 | 16 | 11 | 12 |
| Transfers to Higher Level of Care (Ischemic) | | 26 | 1 | 1 | 2 | 1 | 5 | 3 | 2 | 1 | 1 | 2 | 4 | 1 | 0 | 3 | 2 |
| Transfers to Higher Level of Care (Hemorrhagic) | | 14 | 2 | 3 | 1 | 4 | 0 | 2 | 1 | 1 | 2 | 1 | 2 | 1 | 1 | 2 | 2 |
| TOTAL NUMBER OF PATIENTS | | 763 | 56 | 50 | 69 | 82 | 70 | 55 | 46 | 75 | 61 | 44 | 58 | 63 | 57 | 62 | 60 |
| Total # of Pts who rec'd thrombolytic (Admitted/Transferred) | | 40 | 4 | 0 | 4 | 3 | 7 | 4 | 4 | 5 | 5 | 2 | 6 | 4 | 3 | 2 | 2 |
| % of thrombolytics - Inpatient & Transfers | | 9% | 11% | 0% | 11% | 9% | 18% | 15% | 16% | 11% | 19% | 6% | 7% | 9% | 9% | 5% | 6% |
| % Appropriate vital sign monitoring post thrombolytics | 90% | 83% | 100% | 100% | 25% | 100% | 86% | 50% | 50% | 100% | 80% | 100% | 50% | 100% | 100% | 100% | 100% |
| Rate of hemorrhagic complications for thrombolytics pts | 0% | 7% | 0% | NA | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Core Measure: OP-23 Head CT/MRI Results | 72% | 78% | 100% | NA | 67% | 100% | 100% | 67% | 0% | 100% | 33% | 100% | 60% | 100% | 100% | 100% | 75% |
| % Appropriate stroke order set used (In-Patient) | 90% | 92% | 96% | 97% | 96% | 94% | 96% | 91% | 96% | 97% | 96% | 94% | 95% | 92% | 96% | 92% | 88% |
| % Appropriate stroke order set used (ED) | 90% | 87% | 90% | 80% | 83% | 91% | 95% | 92% | 82% | 88% | 88% | 93% | 91% | 87% | 82% | 76% | 78% |
| STK-1 VTE (GWTG, TJC) | 85% | 88% | 79% | 88% | 100% | 89% | 96% | 89% | 79% | 83% | 88% | 83% | 100% | 94% | 90% | 79% | 73% |
| STK-2 Discharged on Antithrombotic (GWTG, TJC) | 85% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 97% | 100% |
| STK-3 Anticoag for afib/aflutter ordered at Dc (GWTG, TJC) | 85% | 95% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| STK-4 Thrombolytics Given within 60 min (GWTG, TJC) | 75% | 92% | 100% | 0% | NA | NA | NA | NA | 100% | NA | 50% | 100% | 100% | NA | 100% | 100% | NA |
| STK-5 Early Antithrombotics by end of day 2 (GWTG, TJC) | 85% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 97% | 100% | 100% | 97% |
| STK-6 Discharged on Statin (GWTG, TJC) | 85% | 98% | 100% | 100% | 100% | 100% | 100% | 100% | 94% | 100% | 100% | 100% | 94% | 97% | 94% | 96% | 94% |
| STK-8 Stroke Education (GWTG, TJC) | 75% | 99% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 97% | 91% | 94% | 91% |
| STK-10 Assessed for Rehab (GWTG, TJC) | 75% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 97% |
| % Dysphagia Screen prior to po intake (GWTG) | 75% | 86% | 84% | 83% | 88% | 87% | 79% | 85% | 74% | 77% | 83% | 71% | 83% | 75% | 80% | 71% | 71% |
| % Smoking Cessation (GWTG) | 85% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 86% |
| % LDL Documented (GWTG) | 75% | 99% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 96% | 100% | 100% | 97% | 97% | 97% | 100% | 97% |
| Intensive Statin Therapy (GWTG) | 75% | 96% | 97% | 96% | 100% | 97% | 93% | 88% | 94% | 100% | 100% | 100% | 94% | 97% | 94% | 96% | 94% |
| % tPA Arrive by 3.5 Hrs; Treat by 4.5 Hrs (GWTG) | 75% | 100% | 100% | NA | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| % NIHSS Reported (GWTG) | 75% | 97% | 97% | 96% | 97% | 97% | 100% | 96% | 100% | 98% | 96% | 100% | 94% | 90% | 90% | 100% | 97% |
| Ischemic ALOS/GMLOS excess | <1.0 | 2.09 | 3.43 | 8.74 | 2.49 | 4.69 | 5.04 | 1.32 | 4.31 | 3.55 | 1.54 | 1.2 | 1.38 | 2.66 | 4.45 | 4.6 | 1.7 |
| Hemorrhagic ALOS/GMLOS excess | <1.0 | 3.72 | 3.43 | 23.45 | 8.39 | 5.61 | 2.99 | 6.83 | 2.42 | 7.68 | 10.93 | 14.18 | 8.22 | 18.8 | 0.9 | 15.4 | -1.25 |
| Ischemic Mortality ACA O/E Ratio (Midas) | <1.0 | 1.18 | 1.3 | 0 | 0.8 | 0.5 | 0 | 1.3 | 0 | 0 | 1.3 | 1.1 | 1.2 | 0.6 | 1.1 | 0.6 | 0 |

2022-2023 In-House Stroke Alert Dashboard

| _ | | | | | Stroke A | Alert Loc | ation | | | | | |
|--------------------|---------|-----|------|------|----------|-----------|--------|-----|-----|-----|-----|------|
| # alerts O-roop | | | | lui. | | | | | | | | |
| # * | July'22 | Aug | Sept | Oct | Nov | Dec | Jan'23 | Feb | Mar | Apr | May | June |
| ■3W | 1 | | | | 1 | 2 | 1 | | | | 1 | 1 |
| ■ 4S | 6 | 2 | 7 | 3 | 4 | 1 | 3 | | 1 | 1 | 3 | 2 |
| ■ 2S | | | | 1 | 2 | | | 1 | 1 | 1 | 1 | 1 |
| 3 S | 2 | | | | 1 | | | | | | | 1 |
| ■ Cath Lab | | | | 1 | 1 | | | | | | | 1 |
| ■ CVICU | 1 | | | 1 | | 1 | | | 1 | | | 1 |
| ■ ICU | | | | | 1 | | 1 | | | | 1 | |
| ■4N | | | | 1 | 1 | 2 | 1 | | 1 | | | |
| ■3N | | 1 | 1 | 1 | 4 | | | | | | | |
| ■ 4T | | | 1 | | 2 | | 1 | | 1 | | | |
| ■ PACU | | | | | | | | | | | | |
| ■2N | 1 | 1 | 2 | | | | | 1 | 2 | 2 | 1 | |
| ■5T | 1 | 1 | | 1 | | 3 | 3 | 2 | 2 | 1 | 2 | |
| ■BP | | | | | | | | | | | | |
| ■1E | 2 | 1 | | | 1 | 1 | 1 | | | | | |
| ■MB | | | | | | | | 1 | | | | |
| ■ CT/Nuc | | | | | | 1 | | | | | | |
| ■Endo | | | | | | | | | | | | |




If patients exhibit any new or worsening neuro deficits while in the hospital; RNs are to call an RRT. The RRT RN will evaluate and determine if a stroke alert should be called. The goal from calling RRT to stroke alerts should be <15 minutes.




TJC expectation is that a designated provider is at the bedside within 15 minutes of stroke alert. KDH has designated the RRT RN as the provider for in-house stroke alerts.

32/64


2022-2023
In-House Stroke Alert Dashboard



TJC expectation is that the CT will be read within 45 minutes of arrival. KDH's goal is 30 minutes (red line). The expectation is that the CT will be performed within 20 minutes of alert (green line).




Neurology consultation should occur on all in-house stroke alerts.




Whenever there are new or worsening neurological deficits ≥3 points, the RN should perform a dysphagia screen to evaluate the patient's ability to swallow. 33/64

2022-2023 In-House Stroke Alert Dashboard




ED Patients: TJC expectation is that IV thrombolytics are given within 60 minutes to eligible patients who present for stroke care at least 50% of the time. In-House Stroke alerts: KDH expectation is that IV thrombolytics are given within 60 minutes to eligible patients who have been identified with new or worsening stroke symptoms. In-house thrombolytic administration rarely occurs; however it is tracked to ensure compliance throughout the continuum of care.




KH expectation is that post thrombolytic monitoring is in compliance with our standardized protocol. All key elements must be completed to be determined as compliant.


2022-2023 TRANSFERS FROM ED TO ANOTHER ACUTE CARE FACILITY



Hemorrhagic patients are transferred out for other procedures not done at KH, specifically coiling/clipping of aneurysms or bleeds. The ED Stroke Alert Committee reviews the process on an ongoing basis to help streamline the process, all action items are captured in PDSA document. The Covid 19 pandemic had caused delays in transfer times in 2021 with continued adverse effects due to staffing/resource availability in 2022.




Transfers for ischemic strokes occur primarily if a large vessel occlusion is noted and would be eligible for endovascular treatment. As a result of the efforts made by the ED Stroke Alert Committee door to transfer times have improved; however Covid 19 pandemic had caused delays in transfer times in 2021 with continued adverse effects due to staffing/resource availability in 2022.




This cohort of patients have a large vessel occlusion that would be eligible for endovascular treatment and do not meet criteria for thrombolytic administration. The Covid 19 pandemic had caused delays in transfer times in 2021 with continued adverse effects due to staffing/resource availability in 2022.


2021-2022 Stroke Alert Dashboard



Per KH ED Stroke Alert process; stroke alerts to be called within 5 min for EMS and 10 min for Triage. Since the opening of the new Triage/zone 5 areas (summer of 2021), significant improvements have been noted in the Triage process.




The expectation is that the physician will see the stroke alert patient within 15 minutes of arrival. Improvements made throughout the past year include: early notification from EMS, MD meets the pt at the door upon arrival, scribe documents first seen time in the record.




The expectation is that all stroke alert patients will have a NIHSS completed by a certified ED staff member and/or the attending physician; the primary responsible person is the attending/resident physician. This audit ONLY tracks if attending/resident physician have completed a full NIHSS in the ED record.


2021-2022 Stroke Alert Dashboard



CMS and TJC expectation is that the CT will be performed by 20 minutes and read by 45 minutes of arrival. KH's CT read time goal is 30 minutes




The data in this graph includes all thrombolytic patients which differs from the TJC rate because exclusion criteria is not used. TJC expectation is that IV thrombolytics are given within 60 minutes to eligible patients who present for stroke care. AHA/ASA GWTG expectations were update in 2019 with new IV thrombolytic goal time to 45 minutes at least 75% of the time (when applicable). To meet this goal, continued changes to the stroke alert process have been made.




Stroke alert criteria includes: pt presenting with stroke like symptoms +BE FAST screen, stroke alerts called prior to arrival and up to 1 hour after arrival. Excluded cases: >1 after arrival or if stroke alert was cancelled.


2021-2022 Stroke Alert Dashboard



TJC expectation is that laboratory tests are completed within 45 minutes of arrival. Changes in stroke alert process has been made early 2019 to improve lab verified times. Action items taken: IV start kits in CT rooms with lab tubes, lab label makers in both CT rooms and specimens taken immediately down to lab.



TJC expectation is that EKGs are completed within 45 minutes of arrival.



Dysphagia screening should be completed by the RN on all stroke alert patients prior to any pointake, including meds. Dysphagia screening is part of the ED stroke alert order sets. Goal is 100% compliance.

Sepsis Quality Focus Team Report

July 2023





Acronyms

- ALOS Average Length of Stay
- BC Blood Culture lab test
- Dx Diagnosis
- ED Emergency Department
- EM Emergency Medicine GME Program
- FM Family Medicine GME Program
- GMLOS Geometric Length of Stay
- ICD10 Billing Codes
- LA Lactic Acid Lab Test
- RRT Rapid Response Team
- SEP-1 CMS Sepsis Bundle Measure
- VBG Venous Blood Gas lab test
- VS Vital Signs
- HR Heart Rate
- PPR Peripheral Pulse Rate
- APR Apical Pulse Rate
- IBW Ideal Body Weight
- PNF Provider Notification Form
- OFI Opportunity for Improvement



SEP-1 Early Management Bundle Compliance

CA State Compliance 63% ~ National Compliance 57% ~ Top Performing Hospitals 78%

Percent of patients with sepsis that received "perfect care." Perfect care is the right treatment at the right time.

Goal for FY23 =

Sepsis Quality Focus Team DASHBOARD **CMS SEP-1 Bundle Compliance** FY2020 FY2021 FY2022 Jul-22 Aug-22 Sep-22 Oct-22 Nov-22 Dec-22 Jan-23 Feb-23 Mar-23 Apr-23 May-23 Jun-23 Goal YTD SEP-1 CMS % bundle compliance 77% 84% 75% 76% 62% 66% 60% 100% 74% 66.9% 74.6% 75.0% 78% 82% 63% 20 Number of CMS compliant cases (n) 26 18 16 n/a 198 206 27 21 21 18 15 207 300 25 Total number CMS cases abstracted (d) 31 33 24 21 34 30 20 24 281 n/a 296 276 400 32 % Concurrent bundle compliant cases 75% 78% 84% 85% 77% 79% 78% 87% 83% 83% 84% 87% 81% 91% Number of concurrent compliant cases (n) 646 785 50 n/a 656 402 45 33 38 54 41 33 33 38 37 Number of concurrent cases abstracted (d) n/a 829 1013 835 52 38 46 65 49 47 55 472 Number of Non-Compliant CMS cases with coordinator n/a 0 0 0 Number of Non-Compliant CMS cases without coordinator 6 12 n/a 6 13 12 0 77 0% 0% 8% 8% 0% % of Non-Compliant CMS cases with coordinator n/a 0% 0% 8% 0% 100% % of Non-Compliant CMS cases without coordinator n/a 100% 100% 100% 100% 100% 92% 92% 92% 0% 88% **KEY** >10% away from goal Within 10% of goal Within 5% of goal Outperforming/meeting goal

SEP-1 Early Management Bundle Compliance

CA State Compliance 63% ~ National Compliance 57% ~ Top Performing Hospitals 78%


Percent of patients with sepsis that received "perfect care." Perfect care is the right treatment at the right time.

| | Sepsis Quality Focus Team DASHBOARD | | | | | | | | | | | | | | | | |
|---|-------------------------------------|---------------------|--------|--------|--------|--------|--------------------------------------|--------|--------|--------|--------|----------------------------|--------|--------|--------|--------|-----|
| | Goal | FY2020 | FY2021 | FY2022 | Jul-22 | Aug-22 | Sep-22 | Oct-22 | Nov-22 | Dec-22 | Jan-23 | Feb-23 | Mar-23 | Apr-23 | May-23 | Jun-23 | YTD |
| SEP-1 Bundle Elements | | | | | | | | | | | | | | | | | |
| 3 hr SEP-1 Bundle % Compliance | 95% | 76.0% | 78.6% | 88.0% | 81% | 87% | 82% | 79% | 86% | 68% | 75% | 70% | 100% | 67% | | | 79% |
| 3hr SEP-1 BundleTotal Patients abstracted (d) | n/a | 296 | 276 | 401 | 32 | 31 | 33 | 24 | 21 | 34 | 32 | 30 | 20 | 24 | | | 281 |
| % Antibiotics adminstered | 95% | 97.3% | 95.7% | 93.0% | 91% | 100% | 97% | 96% | 90% | 85% | 97% | 83% | 100% | 100% | | | 94% |
| % Blood Cultures drawn | 95% | 93.8% | 92.0% | 93.0% | 97% | 97% | 91% | 100% | 100% | 83% | 94% | 96% | 100% | 83% | | | 94% |
| % Lactic Acid drawn | 95% | 95.6% | 97.9% | 98.0% | 97% | 100% | 100% | 100% | 100% | 96% | 93% | 100% | 100% | 100% | | | 99% |
| % Fluid Resuscitation completed | 95% | 88.3% | 90.7% | 92.0% | 88% | 79% | 89% | 75% | 86% | 100% | 84% | 75% | 100% | 56% | | | 83% |
| | | | | | | | | | | | | | | | | | |
| 6 hr bundle % Compliance | 95% | 85.4% | 93.5% | 90.0% | 95% | 95% | 100% | 94% | 87% | 86% | 86% | 80% | 100% | 94% | | | 92% |
| 6hr SEP-1 BundleTotal Patients abstracted (d) | n/a | 186 | 170 | 250 | 21 | 20 | 18 | 17 | 15 | 14 | 21 | 15 | 16 | 16 | | | 173 |
| % Repeat LA drawn | 95% | 89.6% | 94.0% | 92.0% | 100% | 95% | 100% | 94% | 87% | 86% | 86% | 80% | 100% | 94% | | | 92% |
| % Reassessment completed | 95% | 92.9% | 98.5% | 91.0% | 90% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | | | 99% |
| % Vasopressors initated when indicated | 95% | 93.30% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | | | 100 |
| Sepsis Alert Measures | | | | | | | | | | | | | | | | | |
| Total Number of Coordinator-Involved Alerts | | | | | 470 | 480 | 473 | 734 | 623 | 472 | 482 | 534 | 504 | 429 | | | 520 |
| % of alerts that resulted in a time zero | | | | | 11% | 8% | 10% | 9% | 8% | 8% | 8% | 9% | 11% | 10% | | | 9% |
| KE | ΕY | >10% away from goal | | | | | Within 10% of goal Within 5% of goal | | | | | Outperforming/meeting goal | | | | | |



Sepsis Any Diagnosis - Outcomes Observed/Expected (o/e) Mortality

SEPSIS ANY DIAGNOSIS o/e MORTALITY FY 2023 (July 2022 - March 2023)




- Ratio < 1.0 indicates that at least expected deaths do not exceed actual (Lower ratio is better)
- Best performing facilities have o/e ratios significantly lower than 1.0 (i.e. 0.6)

Midas Risk Adjusted Model v5 comparison analysis (582-624 sites)



Sepsis Any Diagnosis - Outcomes Length of Stay






- 24% decrease in ALOS from FY16 (ALOS=7.71) to FY23 (ALOS=5.85)
- *FYTD23 Kaweah Health ALOS 5.85 days vs. CMS GMLOS 3.88 Difference of 1.96 days > GMLOS.
- COVID-19 cases removed in FY20-23. SEP-1 bundle does not apply to COVID-19 patients.

*FYTD23: July 2022 - Jan 2023



Sepsis 1-Hour to Treatment Implementation to Reduce Morbidity and Morality

- Research suggests that early recognition of sepsis followed by prompt treatment are key factors for reducing sepsis-related mortality
- Kumar et al. identified a 7.6% increase in mortality for every hour sepsis is left untreated
- At Kaweah Health, recent sepsis-related mortality trends reflect an uptick in mortality
- ED physicians/residents/educators, ISS, pharmacy, and the Quality Sepsis Team are collaborating to identify new strategies to reduce sepsis-related mortality with strong support from BOD/Executive Leadership
- Implementation of a standard ED 1-hour sepsis bundle is been rolled out in the ED with goal of Early Goal-Directed Therapy for suspicion of sepsis
- The proposed 1-hour bundle includes pre-selected orders for blood cultures and serial lactate collection, minimal broad-spectrum antibiotic option, and one crystalloid option





Sepsis QFT Actions & Next Steps

- Key Improvement strategies in process:
 - 1. Educational activity for Hospitalist on understanding Sepsis from a CMS Perspective & one hr. bundle to decrease mortality (5/18/23). Follow up meeting planned for July, 2023
 - 2. Educational activity for Intensivist on understanding Sepsis from a CMS Perspective & one hr. bundle to decrease mortality (6/22/23).
 - 3. Secure resident engagement & Support (Sepsis team ongoing communication with chief residents)
 - 4. ED providers education by Dr. Tu & Dr. Pho
 - Ongoing education activities by Clinical Education in partnership with Sepsis Team
 - 6. Healthy Analytics Sepsis Data retrieval tool being developed to track 1-hr. bundle
 - 7. Standing educational activities for GME residency: Sepsis SIM and Sepsis didactic every 18 months
 - 8. Development of a Sepsis 1- hour bundle power plan



Blood culture collection (before antibiotics)

Vasopressors*

Oxygen supplementation*

Crystalloids / colloids*

Antibiotics (broad-spectrum, parental)

Lactic acid monitoring (serial collection)

*When appropriate





weah Health Clinical Education

Process Change/New Knowledge

Sepsis: One Hour Bundle Go-live in ED: June

The 3-hour Sepsis bundle is changing to the 1-hour Sepsis bundle. Early broad-spectrum antibiotic and fluid administration after blood culture collection stands as the pinnacle of sepsis management. By completing thes elements into a 1-hour bundle, we can provide better care and save lives.

B VOCAL If you are suspicious of sensis notify the Provider

B is for Blood Culture collection (these need to be drawn prior to antibiotic administration)

Kaweal This will help future Providers (inpatient) alter plan of care with proper identification of the bacterial source

V is for Vasopressors (when appropriate)

Did fluid resuscitation fix hypotension? If not, consider norepinephrin

O is for Oxygen therapy (when appropriate)

Does the patient show signs of altered mentation? Are they complaining of SOB? Are they tachypneic? If so, include oxygen supplementation.

C is for Crystalloids/Colloids (when appropriate)

Is the patient hypotensive? Do they have a lactic acid > or = 4? Do they respond to a passive leg raise? If so, consider fluid therapy follood products work too!!)

NS, LR, PRBC's, Albumin, Plasma, etc.

Process Change/New Knowledge

A is for Antibiotics (intravenous, broad-spectrum)

Administer as soon as blood cultures are drawn (be mindful to print and scan all lab labels before scanning meds)

L is for Lactic Acid (draw the first one with the blood cultures)

Is the initial lactic acid >2? If so, we need to draw another one after antibiotic administration. If not, a repeat LA is not needed (double check with Provider if they want another one)

The 1-Hour Sepsis Challenge

Draw Blood Cultures and Lactic Acid

Give Crystalloids/Colloids

Give Antibiotics

Remember: Time is Tissue.





Sepsis QFT Actions & Next Steps

- Key Improvement strategies in process:
 - 1. Collaborating with California Quality Improvement Organization HSAG & Best performing facility to mirror best practices
 - 2. Streamlined definition for suspicion of Sepsis to trigger the 1-hour bundle
 - 3. Eliminate Sepsis 1A power plan
 - Continue education/follow-up with providers during concurrent review of cases
 - 5. Improve communication regarding blood culture collection between nurse, phlebotomist etc.
 - 6. Developed paper Sepsis checklist for assisting in 1-hour bundle task completion and handoff
 - 7. Exploring the use of Sepsis intervention tracker/Sepsis checklist with ISS partners
 - 8. Ongoing weekly Kanban sepsis meetings with ISS partners
 - Acronym developed to assist as cognitive aid to remember SEP-1 Bundle elements: B VOCAL!
 - 10. Exploring development of SIRS Sepsis Alert for ED



Blood culture collection (before antibiotics)

Vasopressors*

Oxygen supplementation*

Crystalloids / colloids*

Antibiotics (broad-spectrum, parental)

Lactic acid monitoring (serial collection)

*When appropriate





veah Health Clinical Education

Process Change/New Knowledge

Sepsis: One Hour Bundle Go-live in ED: June

The 3-hour Sepsis bundle is changing to the 1-hour Sepsis bundle. Early broad-spectrum antibiotic and fluid administration after blood culture collection stands as the pinnacle of sepsis management. By completing thes elements into a 1-hour bundle, we can provide better care and save lives.

B VOCAL If you are suspicious of sensis notify the Provide

B is for Blood Culture collection (these need to be drawn prior to antibiotic administration)

This will help future Providers (inpatient) alter plan of care with proper identification of the bacterial source

V is for Vasopressors (when appropriate)

Did fluid resuscitation fix hypotension? If not, consider norepinephrine

O is for Oxygen therapy (when appropriate)

Does the patient show signs of altered mentation? Are they complaining of SOB? Are they tachypneic? If so, include oxygen supplementation.

C is for Crystalloids/Colloids (when appropriate)

Is the patient hypotensive? Do they have a lactic acid > or = 4? Do they respond to a passive leg raise? If so, consider fluid therapy follood products work too!!)

NS, LR, PRBC's, Albumin, Plasma, etc.

Process Change/New Knowledge

A is for Antibiotics (intravenous, broad-spectrum)

Administer as soon as blood cultures are drawn (be mindful to print and scan all lab labels before scanning meds)

L is for Lactic Acid (draw the first one with the blood cultures)

Is the initial lactic acid >2? If so, we need to draw another one after antibiotic administration. If not, a repeat LA is not needed (double check with Provider if they want another one)

The 1-Hour Sepsis Challenge

Draw Blood Cultures and Lactic Acid

Give Crystalloids/Colloids

Give Antibiotics

Remember: Time is Tissue.





Sepsis QFT Actions & Next Steps

Next Steps:

- One-Hour Bundle power form planned go live date 6/20/23
- Review suggested improvement strategies with complete stakeholder group, and solicit input to expand list & update as needed
- Prioritize and execute improvement strategies
- Ongoing evaluation for the "One-Hour" Sepsis bundle to reduce Sepsis mortality
- Track & Trend Sepsis Mortality



Dr. LaMar Mack, Medical Director, Quality and Patient Safety Sandy Volchko, RN-Director, Quality and Patient Safety. Ext. 2169 Erika Pineda, RN-Manager, Quality and Patient Safety. Ext. 2876 Ryan Smith, RN-Sepsis Coordinator. Ext. 5905 Jared Cauthen, RN-Sepsis Coordinator. Ext. 6903





Methicillin-Resistant Staphylococcus Aureus (MRSA)

Quality Focus Team Report July 2023

Ouality Focus Team Members

- Jag Batth Chief Operating Officer (ET)
- Kylie Jarrell Admin Assistant Environmental Services, Laundry/Linen, & Patient Transport Service (Recorder)
- Tendai Zinyemba Director of Environmental Services. Laundry/Linen, & Patient Transport Service (Chair)
- Shane Reynolds Assistant Nurse Manager 4N (Co-Chair)
- Justin Ma Infectious Disease Pharmacist
- Amy Baker Director of Renal Services
- Sandy Volchko Director of Quality & Patient Safety
- Shawn Elkin Infection Prevention & Control Manager
- Joetta Denny Infection Prevention
- Gloria Dickerson Clinical Educator
- Johnny Mata Respiratory Care Manager

















MRSA- FY23 Goals

Healthcare onset MRSA bloodstream infection rate that does not exceed a standardized infection ratio of 0.726 or (<0.5 cases a month/1.5 cases a quarter/6 cases a year)

We reported 5 MRSA BSI events July 2022 – May 2023. (Only 1 was related to COVID-19 during FY)

*based on July-August 2022 NHSN predicted












^{**}Standardized Infection Ratio (SIR) is the number of patients with a healthcare acquired infection (HAI) divided by the number of patients who were predicted to have an HAI.

MRSA Bloodstream Infection is impacted by the number of inpatient days for a given time period.

Background Data – MRSA Bloodstream Infection Events

Number of MRSA Bloodstream Infection events at Kaweah Health from over calendar years 2017 through May 2023 with emphasis on implementation of MRSA Quality Focus Team and MRSA Nasal Decolonization Pilot Study.



Number of MRSA BSI events dipped during November 2019 through March of 2020 in part due to the electronic hand hygiene system pilot on 4N, and ICU and the added attention given to healthcare associated infections (e.g. CLABSI/CAUTI) with Kaizen Projects and initiation of GEMBA Rounds. The increase in MRSA BSI events after March 2019 was associated with the COVID-19 pandemic, extended lengths of stays, blood culturing practices, and source control of the primary infection site. FY2023 has demonstrated a significant decrease in MRSA BSI events proximal to the time automated orders for Mupirocin decolonization treatment went live for 4N and ICU.

| Fiscal Year | Infection | SIR |
|-------------|-----------|-------|
| 2018 | 9 | 2.958 |
| 2019 | 7 | 1.97 |
| 2020 | 4 | 0.923 |
| 2021 | 17 | 2.648 |
| 2022 | 12 | 1.371 |
| 2023 | 5 | 0.620 |














Background Data – MRSA Bloodstream Infections & Standardized Infection Ratio Trend

| Fiscal Year | Infection | SIR |
|-------------|-----------|-------|
| 2018 | 9 | 2.958 |
| 2019 | 7 | 1.97 |
| 2020 | 4 | 0.923 |
| 2021 | 17 | 2.648 |
| 2022 | 12 | 1.371 |
| 2023 | 5 | 0.620 |















BioVigil Data - Hand Hygiene Opportunities


















ATP Data

Filter: Area = '5T,Cath Lab,CVICU,CVOR,ICU,Main OR,OB OR,OR', Date Collected Between 2022-01-01 and 2023-06-30



| Qtr | % Pass | Tests completed |
|--------|--------|-----------------|
| 2022Q1 | 76% | 429 |
| 2022Q2 | 83% | 283 |
| 2022Q3 | 87% | 252 |
| 2022Q4 | 67% | 351 |
| 2023Q1 | 80% | 343 |
| 2023Q2 | 82% | 293 |
| Avg | 79% | |

kaweahhealth.org








ter: Area – 51,Cath Lab,CVICO,CVOR


Summary Report

Filter: Area = '5T,Cath Lab,CVICU,CVOR,ICU,Main OR,OB OR,OR', Date Collected Between 2022-01-01 and 2023-06-30



Summary Report

Filter: Area = '5T,Cath Lab,CVICU,CVOR,ICU,Main OR,OB OR,OR', Date Collected Between 2023-04-01 and 2023-06-30



Rank Report By Site

Filter: Area = '5T,Cath Lab,CVICU,CVOR,ICU,Main OR,OB OR,OR', Date Collected Between 2022-01-01 and 2023-06-30

| | F | ass | Ma | arginal | 1 | | |
|--------------|-----|--------|----|---------|----|----------|-------|
| Site | # % | | # | 9/6 | # | 96 | Total |
| Call Button | 5 | 31.25% | 0 | 0.0% | 11 | 68.75% | 16 |
| Overbed TBL | 3 | 33.33% | 0 | 0.0% | 6 | 66.67% | 9 |
| Telephone | 5 | 45.45% | 0 | 0.0% | 6 | 6 54.55% | |
| RM Sink | 6 | 46.15% | 0 | 0.0% | 7 | 53.85% | 13 |
| Bedside TBL | 13 | 50.0% | 0 | 0.0% | 13 | 50.0% | 26 |
| Bedrail | 53 | 53.54% | 0 | 0.0% | 46 | 46.46% | 99 |
| Chair | 24 | 63.16% | 0 | 0.0% | 14 | 36.84% | 38 |
| IV Pole | 30 | 66.67% | 0 | 0.0% | 15 | 33.33% | 45 |
| RM Light SW | 2 | 66.67% | 0 | 0.0% | 1 | 33.33% | 3 |
| RR Sink | 18 | 72.0% | 0 | 0.0% | 7 | 28.0% | 25 |
| ORBedControl | 102 | 73.91% | 0 | 0.0% | 36 | 26.09% | 138 |
| OR Table | 216 | 80.3% | 0 | 0.0% | 53 | 19.7% | 269 |
| Miscellanous | 225 | 80.65% | 1 | 0.36% | 53 | 19.0% | 279 |
| Counter | 242 | 81.48% | 0 | 0.0% | 55 | 18.52% | 297 |
| Anes Cart | 179 | 83.64% | 1 | 0.47% | 34 | 15.89% | 214 |
| Back Table | 128 | 85.91% | 0 | 0.0% | 21 | 14.09% | 149 |
| OR Light | 306 | 86.44% | 0 | 0.0% | 48 | 13.56% | 354 |
| Handrail | 8 | 88.89% | 0 | 0.0% | 1 | 11.11% | 9 |
| Flush Handle | 10 | 100.0% | 0 | 0.0% | 0 | 0.0% | 10 |

ATP Data - Plan for sustainable improvement

- Determined our World-class goal to be 90% moving forward no industry benchmark.
- Hired EVS Coordinator for standardized training complete (Julian Medrano currently in training).
- Retraining of all EVS leaders to include certification from ATP reader manufacturer (Neogen) - 100% complete.
 - Streamlined timing and communication on conducting ATP tests.
- Annual competency validation of staff work in progress.
- Track & trend data, to include high touch areas of focus and align needs to analyzed trend.







Root Causes Identified

Culturing Practices

- Late blood cultures eliminating present-on admission designation.
- Serial blood cultures that exceed 14-day repeat infection timeframe (RIT).
- Positive MRSA serial blood cultures that exceed 14 days are considered a new event and healthcare acquired.
- Serial positive cultures across patient room assignments.

Source Control

- Endocarditis
 (Life-threatening inflammation of the inner lining of heart chambers and valves)
- Osteomyelitis
 (Inflammation or swelling that occurs in the bone)
 maybe a contributing factors to seeding of the bloodstream.
- Delayed consultations, incomplete diagnostic studies, or avoidance of obtaining a specimen from the likely source of infection.
- Without addressing the primary source of infection there will be continued seeding of the bloodstream.













MRSA QFT: Key Strategies

- Automated Mupiriocin MRSA nasal decolonization treatment (house-wide go-live scheduled for 7/17/2023
- Improved utilization of the BioVigil electronic hand hygiene surveillance system
- Clinic based 'Patient as observer' hand hygiene program using NRC Picker Survey tool
- Do You Disinfect Every time (D.U.D.E.) Campaign
- Environmental cleaning quality metrics Adenosine Triphosphate (ATP) monitoring
- Targeted use of Electrostatic Disinfectant Sprayer that produces an electrical charge so that disinfectant attaches to surfaces directly and indirectly facing the sprayer, ensuring thorough coverage over surfaces











MRSA QFT: Recommendations

- 1. Provider involvement needed to help:
 - Process to effectively order/perform blood cultures
 - Prostaff will be reviewing/approving an evidence-based decision flow map for blood culturing practices
 - Decision flow map addresses source control monitoring (i.e. endocarditis, osteomyelitis, and device related sources)
- 2. Double down on MRSA Key strategies shared on prior slide (Decolonization; Hand hygiene; Patient care environment cleaning & disinfection etc...)















The pursuit of healthiness



Outstanding Health Outcomes Update

Sandy Volchko DNP, RN, CPHQ, CLSSBB Director Quality & Patient Safety

July 2023



FY23 Clinical Quality Goals

 July 22 – May 23
Higher is Better
 FY23 Goal
 FY22 Goal

 SEP-1
(% Bundle Compliance)
 74%
 ≥ 77%
 76%
 ≥ 75%

Our Mission

Health is our passion.

Excellence is our focus.

Compassion is our promise.

Our Vision

To be your world-class healthcare choice, for life

Percent of patients with this serious infection complication that received "perfect care". Perfect care is the right treatment at the right time for our sepsis patients.

| Lower is Better | July 2022 | Aug 2022 | Sept 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | June 2023 | Estimated Annual Number Not to Exceed to Achieve Goal* | FYTD SIR** (number of actual/ number expected) | FY23 Goal (VBP 2024; National Mean 2019) | FY22 FY21 FY20 |
|---|--------------|-------------|--------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|--------------|--|--|--|-----------------------|
| CAUTI Catheter Associated Urinary Tract Infection Excluding COVID INCLUDING COVID-19 PATIENTS | 1 | 1 | 2 | 1 | 2 | 3 | 0 | 0 | 0 | 1 0 | 2 | 0 | 14 (23 predicted over 12 months) | 0.55 0.596 Including COVID | ≤0.650 | 1.092 0.54 1.12 |
| CLABSI Central Line Associated Blood Stream Infection Excluding COVID INCLUDING COVID-19 PATIENTS | 2 | 0 | 0 | 1 | 1 0 | 2 | 1 | 1 | 1 0 | 2 | 0 | 3 | 10 (17 predicted over 12 months) | 0.98 1.034 Including COVID | ≤0.589 | 1.132 0.75 1.20 |
| MRSA Methicillin-Resistant Staphylococcus Aureus Excluding COVID INCLUDING COVID-19 PATIENTS | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 5 (8 predicted over 12 months | 0.63 0.676 Including COVID | ≤0.726 | 1.585 2.78 1.02 |

*based on July 2021-June 2022 NHSN predicted

^{**}Standardized Infection Ratio is the number of patients who acquired one of these infections (excluding COVID patients) while in the hospital divided by the number of patients who were expected.

